The Californer - Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)

Trending...

Caring Brands Inc. (N A S D A Q: CABR) $CABR Intends to Launch 5 Products Over the Next 2 Years in Addition to In-Licensing Additional Products.

FORT PIERCE, Fla. - Californer -- Caring Brands Inc. (N A S D A Q: CABR) $CABR is advancing a differentiated consumer health strategy built around exclusive licensing, patented formulations, and clinically validated products. The company's latest milestone—securing an exclusive global license to manufacture and commercialize Emesyl, an over-the-counter nausea relief product—adds a meaningful new growth vector while reinforcing its portfolio-based approach to scale.

The Emesyl agreement positions CABR to participate in a global nausea treatment market projected to exceed $6.23 billion, while complementing its existing dermatology and hair-growth offerings and accelerating its multi-year product launch roadmap.

Exclusive Global Rights to Emesyl Unlock New Commercial Opportunity

On January 5, Caring Brands announced it entered into an exclusive worldwide license agreement with Itonis, Inc. to manufacture, market, and distribute Emesyl, an established OTC nausea relief product.

Under the agreement:

CABR holds exclusive global commercialization rights
CABR assumes control of manufacturing, marketing, sales strategy, and global distribution
Itonis will provide technical data, formulation details, historical sales information, and intellectual property support
The agreement includes royalties based on future net sales
CABR may earn equity in Itonis, tied to defined revenue milestones

According to QY Research, the global market for nausea treatment and related therapies is projected to exceed USD $6.23 billion in 2025, highlighting the scale of the opportunity as CABR revitalizes and expands Emesyl's market presence.

More on The Californer

CEO Glynn Wilson commented:

"Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence."

Portfolio-Driven Strategy with Multiple Revenue Streams

Caring Brands is building a diversified portfolio of unique, patented, and clinically validated products, reducing reliance on any single asset while expanding its total addressable market.

Current and pipeline products include:

Hair Enzyme Booster – for hair loss
Photocil – for psoriasis and vitiligo
CB-101 – in development for eczema
NoStingz – a sunscreen designed to prevent jellyfish stings
Emesyl – OTC nausea relief (exclusive global license)

The company is already generating revenue through:

Direct U.S. product sales
International licensing partners, including India

CABR plans to launch five products over the next two years, while continuing to in-license additional assets, expanding both geographic reach and category exposure.

Proven Management Execution Model

CABR's leadership team brings a track record of strategic acquisitions, rapid product development, IP creation, and licensing execution. The company's model emphasizes:

Leveraging existing clinical validation
Accelerating time-to-market
Controlling branding and commercialization
Monetizing products via both direct sales and licensing

This disciplined approach allows Caring Brands to scale efficiently while managing development risk.

More on The Californer

N A S D A Q Uplisting Strengthens Capital Markets Position

In November, Caring Brands completed a $4.0 million underwritten public offering in conjunction with its uplisting to the N A S D A Q Capital Market.

Key transaction details:

1,000,000 shares priced at $4.00 per share
$4.0 million in gross proceeds
45-day option for underwriters to purchase up to 150,000 additional shares
Underwriter: D. Boral Capital LLC

The proceeds are intended for:

Marketing and sales expansion
Working capital
Repayment of certain debt

The Nasdaq listing enhances CABR's visibility, liquidity, and access to institutional investors as it advances multiple commercialization initiatives.

Investment Perspective

Caring Brands is positioning itself as a portfolio-driven consumer health company with multiple near-term and mid-term catalysts, including:

Exclusive global rights to Emesyl in a $6.23B market
Planned five product launches over the next two years
Existing revenue from dermatology and hair-growth products
A scalable licensing and commercialization framework
Strengthened balance sheet following its Nasdaq uplisting

As Emesyl progresses toward global rollout and additional products come to market, CABR offers investors exposure to diversified OTC health opportunities driven by execution and disciplined expansion.

Company: Caring Brands Inc. (N A S D A Q: CABR)
Media & Investor Contact:
Brian S. John, Chief Investment Officer
Email: info@caringbrands.com
Phone: (561) 896-7616

Website: www.caringbrands.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website